Clinical Trial Update: A 4-week Study to Test Different Doses of BI 1265162 in Adolescents and Adults With Cystic Fibrosis Using the Respimat® Inhaler - BALANCE - CF™1 [Phase 2]

View source ↗

Summary

Phase 2 trial assessing multiple doses of BI 1265162 in adolescents and adults with cystic fibrosis using the Respimat inhaler; study terminated with posted res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• BI 1265162 (BI 1265162)
• Respimat

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Cystic Fibrosis | Phase 2 | Status: TERMINATED | Results posted: 2021-06-04